Literature DB >> 9879785

Mode of inheritance in mood disorder families according to fluvoxamine response.

A Serretti1, L Franchini, M Gasperini, R Rampoldi, E Smeraldi.   

Abstract

Mood disorders are known to cluster within families, but the mode of transmission remains largely unknown. The purpose of our analysis was to determine whether selection of a sample that was homogeneous in its response to an antidepressant provided stronger evidence for a single major locus. Complex segregation analysis was applied to a sample of 171 Italian families of bipolar and unipolar probands that were responsive to the antidepressant fluvoxamine. We used regressive logistic analyses to determine the best fit from among environmental, arbitrary Mendelian, dominant, recessive and additive models. For the 171 affective families with probands that were responsive to the antidepressant fluvoxamine, a Mendelian model of inheritance was rejected. When considering 68 families of bipolar probands, the best fit was obtained for a Mendelian dominant model of transmission. The identification of a Mendelian mode of transmission in bipolar subjects who were selected according to their response to fluvoxamine supports the use of a pharmacological criterion as a tool for identifying true genetic disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879785     DOI: 10.1111/j.1600-0447.1998.tb10117.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  14 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-wide Additive Genetic Effects on Depression Severity and Treatment Response.

Authors:  Rohan H C Palmer; Christopher G Beevers; John E McGeary; Leslie A Brick; Valerie S Knopik
Journal:  Clin Psychol Sci       Date:  2016-10-19

Review 3.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

4.  CREB1 gene polymorphisms combined with environmental risk factors increase susceptibility to major depressive disorder (MDD).

Authors:  Peng Wang; Yanjie Yang; Xiuxian Yang; Xiaohui Qiu; Zhengxue Qiao; Lin Wang; Xiongzhao Zhu; Hong Sui; Jingsong Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder.

Authors:  Dena Firouzabadi; Negar Firouzabadi; Kiana Kalani; Kamyar Zomorrodian; Elham Shirazi Tehrani
Journal:  Eur J Clin Pharmacol       Date:  2018-10-15       Impact factor: 2.953

6.  Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.

Authors:  Firoza Mamdani; Marcelo T Berlim; Marie-Martine Beaulieu; Gustavo Turecki
Journal:  World J Biol Psychiatry       Date:  2013-03-26       Impact factor: 4.132

7.  Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder.

Authors:  Alessandro Serretti; Paola Artioli; Raffaella Zanardi; Cristina Lorenzi; David Rossini; Cristina Cusin; Alessia Arnoldi; Marco Catalano
Journal:  Psychopharmacology (Berl)       Date:  2004-07-10       Impact factor: 4.530

8.  Psychiatric comorbidity and suicide risk in patients with chronic migraine.

Authors:  Maurizio Pompili; Gianluca Serafini; Daniela Di Cosimo; Giovanni Dominici; Marco Innamorati; David Lester; Alberto Forte; Nicoletta Girardi; Sergio De Filippis; Roberto Tatarelli; Paolo Martelletti
Journal:  Neuropsychiatr Dis Treat       Date:  2010-04-07       Impact factor: 2.570

Review 9.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

10.  Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study.

Authors:  Mushtaq A Margoob; Dhuha Mushtaq; Imtiyaz Murtza; Huda Mushtaq; Arif Ali
Journal:  Indian J Psychiatry       Date:  2008-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.